Immunome Inc Forecast, price target & analysts
Immunome Inc Target price 2025 - Analyst rating & recommendation
Immunome Inc Classifications & Recommendation:
Immunome Inc Price Target
| Target Price | $22.44 |
| Price | $18.42 |
| Potential |
21.82%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Immunome Inc 2026 .
The average Immunome Inc target price is $22.44.
This is
21.82%
register free of charge
$39.90
116.61%
register free of charge
$18.18
1.30%
register free of charge
|
|
| A rating was issued by 18 analysts: 17 Analysts recommend Immunome Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Immunome Inc stock has an average upside potential 2026 of
21.82%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 9.04 | 7.69 |
| 35.52% | 14.98% | |
| EBITDA Margin | -1,680.20% | -2,627.63% |
| 733.26% | 56.39% | |
| Net Margin | -3,240.71% | -2,606.26% |
| 325.38% | 19.58% |
13 Analysts have issued a sales forecast Immunome Inc 2025 . The average Immunome Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Immunome Inc EBITDA forecast 2025. The average Immunome Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Immunome Inc Analysts have issued a net profit forecast 2025. The average Immunome Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.00 | -2.18 |
| 7.06% | 56.40% | |
| P/E | negative | |
| EV/Sales | 184.32 |
14 Analysts have issued a Immunome Inc forecast for earnings per share. The average Immunome Inc EPS is
This results in the following potential growth metrics and future valuations:
Current Immunome Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Nov 17 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 22 2025 |
| Craig-Hallum |
Locked
➜
Locked
|
Locked | Sep 05 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 25 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Aug 22 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Lake Street |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Nov 17 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 22 2025 |
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
Sep 05 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 25 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Aug 22 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
Lake Street:
Locked
➜
Locked
|
Apr 02 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
